NORDEN implements restricted share programme for 2019

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
20
NORDEN implements restricted share programme for 2019

ANNOUNCEMENT NO. 5 - 30 JANUARY 2019

NORDEN implements restricted share programme for 2019

In accordance with the adopted remuneration policy for NORDEN, the company has decided to implement a restricted share programme for 2019 similar to the one in 2018.

The overall purpose of the programme is to ensure a shared interest with shareholders and to reward long-term and dedicated work which is deemed to be of value to NORDEN.

Restricted shares will be granted free of charge and remain restricted during a vesting period of 3 years. The programme is expected to be covered by treasury shares. The total number of shares allocated for this programme is 82,452 and the total value of the share programme is USD 1.178.994 (DKK 7.705.436) based on the Volume Weighted Average Price of the NORDEN share as of yesterday, January 29, 2019, which is DKK 93.45.

Restricted shares will be granted to Senior Management, a core group of managers and specialists and certain other staff and upon vesting the recipient will receive 1 NORDEN share of nominally DKK 1 for each vested restricted share.

The decision to grant restricted shares is taken on an annual basis by the Board of Directors. Other than being employed by NORDEN at the time of granting of the restricted shares no conditions are attached to the grant. A grant of restricted shares in one year does not entitle the recipient to receive restricted shares in subsequent years. Where a recipient resigns during the vesting period, non-vested restricted shares will lapse.

Kind regards

Dampskibsselskabet NORDEN A/S

Klaus Nyborg Chairman of the board

  For further information:

Klaus Nyborg, Chairman, tel.: +45 3315 0451 Nicolai Bro Jöhncke, Head of Corporate Communications & CSR, tel.: +45 3315 0451

ANNOUNCEMENT NO. 5 - 30 JANUARY 2019

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring Advances in AI and Digital R&D Innovation by ICON plc

Updated Category News Views 227

Recent Developments in AI and Digital Innovation by ICON plc ICON plc, a globally recognized clinical research organization (NASDAQ: ICLR), has recently conducted an extensive survey exploring the integration of Artificial Intelligence (AI) and digital tools within clinical research. Engaging with over 100 professionals in the biotech and pharmaceutical industries across...

Continue Reading
Tesla's Self-Driving Claims Under Fire: Industry Reactions

Updated Category News Views 167

Tesla's License Suspension in California Recently, a court in California announced a significant development affecting Tesla Inc. (NASDAQ: TSLA). The court decided to suspend Tesla's license to sell vehicles for 30 days due to a lawsuit concerning misleading claims about the company's Full Self-Driving (FSD) technology. If Tesla does not adapt its policies within 90 days,...

Continue Reading
Sunnova Energy Faces Challenges Amid Revenue Declines in 2024

Updated Category News Views 384

Sunnova Energy Experiences Financial Struggles Sunnova Energy International Inc. (NOVA) has encountered a challenging period, with its shares trading lower in the premarket on Monday following a disappointing report detailing its fourth quarter and full-year financial results. The financial landscape for Sunnova shows a revenue of $224.127 million, which unfortunately...

Continue Reading
Kerusso's Important Contributions in Faith and Community Work

Updated Category News Views 133

Kerusso's Inspiring Charitable Contributions in 2025 Kerusso Activewear, a prominent Christian apparel and gift brand, has ended the year with a remarkable achievement of over $400,000 in charitable contributions. This reflects their steadfast commitment to enriching lives through faith-based approaches and generous support for individuals in need. Growing Demand for...

Continue Reading
Prelude Therapeutics and Incyte Join Forces for JAK2JH2 Inhibitor

Updated Category News Views 101

Prelude Therapeutics Partners with Incyte on JAK2V617F Program Incyte establishes exclusive option to acquire Prelude’s innovative programs These inhibitors have the potential to modify disease outcomes in patients with myeloproliferative neoplasms (MPNs) Prelude Therapeutics, a clinical-stage oncology company, has recently made headlines with an exciting announcement...

Continue Reading